NCT00193466 Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE2
NCT00185510 Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis Status COMPLETED Phase PHASE4
NCT00185458 Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT). Status COMPLETED Phase PHASE3
NCT00185419 A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception Status COMPLETED Phase PHASE3
NCT00185393 Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy Status COMPLETED Phase PHASE3
NCT00185380 Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS) Status COMPLETED Phase PHASE2
NCT00185341 Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain Status COMPLETED Phase PHASE2
NCT00185315 Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension Status COMPLETED Phase PHASE3
NCT00185302 Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma Status COMPLETED Phase PHASE2
NCT00185289 Study to Investigate Efficacy and Safety of a New Oral Contraceptive Status COMPLETED Phase PHASE3
NCT00185276 Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries Status COMPLETED Phase PHASE3
NCT00185250 Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy Status COMPLETED Phase PHASE2
NCT00185237 Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch Status COMPLETED Phase PHASE3
NCT00185224 Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive Status COMPLETED Phase PHASE2
NCT00185211 BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study Status COMPLETED Phase PHASE3